All | Anti-TNF agents initiators | Non-anti-TNF agents initiators | Standardized absolute mean difference | |
---|---|---|---|---|
Total, n | 913 | 762 | 151 | |
Age (median, IQR), years | 56 [48,65] | 55 [47,64] | 60 [51,69] | 0.349 |
Female, n (%) | 675 (77.2) | 563 (76.9) | 112 (78.9) | 0.047 |
Caucasian, n (%) | 708 (80.8) | 596 (81.2) | 112 (78.9) | 0.058 |
RA disease duration (median, IQR), years | 2 [1,7] | 2 [1,6] | 4 [1,11] | 0.294 |
CDAI (median, IQR) | 27 [20,37] | 26 [20,36] | 28 [20,38] | 0.115 |
DAS28-CRP (median, IQR) | 4.8 [4.1,5.5] | 4.9 [4.1,5.5] | 4.6 [3.9,5.4] | 0.114 |
Biologic Monotherapy, n (%) | 221 (24.2) | 178 (23.4) | 43 (28.5) | 0.117 |
Concurrent DMARDs, n (%) | 692 (75.8) | 584 (76.6) | 108 (71.5) | 0.117 |
MTX only, n (%) | 486 (53.2) | 425 (55.8) | 61 (40.4) | 0.311 |
MTX dose (med, IQR) mg/week | 20 [15,20] | 20 [15,20] | 20 [15,20] | 0.149 |
MTX plus other DMARDs, n (%) | 95 (10.4) | 81 (10.6) | 14 (9.3) | 0.045 |
Leflunomide only, n (%) | 39 (4.3) | 29 (3.8) | 10 (6.6) | 0.127 |
Sulfasalazine only, n (%) | 13 (1.4) | 10 (1.3) | 3 (2) | 0.053 |
Hydroxychloroquine only, n (%) | 33 (3.6) | 27 (3.5) | 6 (4) | 0.023 |
Concomitant prednisone, n (%) | 287 (31.4) | 243 (31.9) | 44 (29.1) | 0.060 |
Prednisone dose (median, IQR) mg | 5 [5,10] | 5 [5,10] | 5 [5,6] | 0.256 |
No use, n (%) | 636 (69.7) | 528 (69.3) | 108 (71.5) | 0.049 |
Prednisone <5 mg, n (%) | 37 (4.1) | 27 (3.5) | 10 (6.6) | 0.140 |
Prednisone 5- <10 mg, n (%) | 134 (14.7) | 111 (14.6) | 23 (15.2) | 0.019 |
Prednisone ≥ 10 mg, n (%) | 106 (11.6) | 96 (12.6) | 10 (6.6) | 0.203 |
Number of prior biologics exposed to (median, IQR) | 0 [0,0] | 0 [0,0] | 0 [0,0] | 0.425 |
Number of prior non-biologic DMARDs exposed to (median, IQR) | 1 [1,2] | 1 [1,2] | 2 [1,2] | 0.343 |
Biologic started at enrollment, n (%) | ||||
Adalimumab | 268 (29.4) | 268 (35.2) | N/A | N/A |
Infliximab | 180 (19.7) | 180 (23.6) | N/A | N/A |
Etanercept | 205 (22.5) | 205 (26.9) | N/A | N/A |
Golimumab | 20 (2.2) | 20 (2.6) | N/A | N/A |
Certolizumab pegol | 89 (9.7) | 89 (11.7) | N/A | N/A |
Rituximab | 15 (1.6) | N/A | 15 (9.9) | N/A |
Abatacept | 100 (11) | N/A | 100 (66.2) | N/A |
Tocilizumab | 36 (3.9) | N/A | 36 (23.8) | N/A |
Co-morbidities, n (%) | ||||
History of Cardiovascular disease* | 71 (7.8) | 54 (7.1) | 17 (11.3) | 0.145 |
History of Hypertension | 203 (28.2) | 165 (26.9) | 38 (35.8) | 0.194 |
History of Diabetes Mellitus | 63 (9) | 52 (8.7) | 11 (11.2) | 0.085 |
Hyperlipidemia (Defined as: Total cholesterol > 240 mg/dL at baseline visit) | 111 (13.5) | 92 (13.3) | 19 (14.2) | 0.025 |
History of Malignancy (includes non -melanoma skin cancers) | 54 (5.9) | 45 (5.9) | 9 (6) | 0.002 |